Name: NUVATION BIO INC (NUVB) Stock
Brand: NUVATION BIO INC
Rating: 6.5 (3 reviews)

NUVB Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Chartmill - Mentions: CYN STEC AGIO KZIA ...

Which stocks are moving on Wednesday?

3 days ago - By: Chartmill - Mentions: MVO AGIO KZIA ZYXI ...

Let's have a look at the top gainers and losers in the middle of the day of today's session.

2 days ago - By: Stocktwits

Nuvation Bio Stock Logs Its Best Session Ever: Wall Street Turns Bullish On Lung Cancer Drug’s Blockbuster Debut

3 days ago - By: Benzinga - Mentions: BFLY ZYXI TXMD AGIO ...

12 Health Care Stocks Moving In Wednesday's Intraday Session

18 days ago - By: The Motley Fool

Nuvation Bio (NUVB) Q3 2025 Earnings Transcript

19 days ago - By: Zacks Investment Research - Mentions: DVAX

Nuvation Bio Inc. (NUVB) Reports Q3 Loss, Tops Revenue Estimates

19 days ago - By: Nuvation Bio Inc.

Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

19 days ago - By: The Motley Fool

Nuvation Bio Chief Scientist Sells 100,000 Shares Under Trading Plan — Here's What to Know About the Stock

23 days ago - By: Nuvation Bio

Nuvation Bio to Participate in Upcoming Investor Conferences

24 days ago - By: Zacks Investment Research - Mentions: MDXG

MiMedx (MDXG) Tops Q3 Earnings and Revenue Estimates

a month ago - By: Nuvation Bio

Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

a month ago - By: Nuvation Bio

Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025

2 months ago - By: New York Stock Exchange - Mentions: ESRT

NYSE Content Advisory: Pre-Market Update + The AW Playmaker Awards Take the Stage at 11 Wall Street

2 months ago - By: Benzinga

4 Analysts Assess Nuvation Bio: What You Need To Know

2 months ago - By: Nuvation Bio

Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer

2 months ago - By: Nuvation Bio

Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

3 months ago - By: Nuvation Bio

Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer

3 months ago - By: Nuvation Bio

Nuvation Bio to Participate in Upcoming Investor Conferences

3 months ago - By: Zacks Investment Research

Nuvation Bio Inc. (NUVB) Just Flashed Golden Cross Signal: Do You Buy?

4 months ago - By: Zacks Investment Research - Mentions: LCTX

Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates

4 months ago - By: Nuvation Bio

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Zacks Investment Research - Mentions: ACAD

Acadia Pharmaceuticals (ACAD) Tops Q2 Earnings and Revenue Estimates

4 months ago - By: Nuvation Bio

Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

4 months ago - By: Nuvation Bio

Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

5 months ago - By: Yahoo Finance - Mentions: GS NUVL

JMP Maintains “Market Outperform” on Nuvation (NUVB) for IBTROZI Launch Plans

5 months ago - By: Nuvation Bio

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers

5 months ago - By: Yahoo Finance - Mentions: TSLA OVID

NUVATION BIO INC (NUVB) Stock News

NUVB Latest News, Press Relases and Analysis

Which stocks are moving on Wednesday?

Let's have a look at the top gainers and losers in the middle of the day of today's session.

Nuvation Bio Stock Logs Its Best Session Ever: Wall Street Turns Bullish On Lung Cancer Drug’s Blockbuster Debut

12 Health Care Stocks Moving In Wednesday's Intraday Session

Nuvation Bio (NUVB) Q3 2025 Earnings Transcript

Nuvation Bio Inc. (NUVB) Reports Q3 Loss, Tops Revenue Estimates

Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Nuvation Bio Chief Scientist Sells 100,000 Shares Under Trading Plan — Here's What to Know About the Stock

Nuvation Bio to Participate in Upcoming Investor Conferences

MiMedx (MDXG) Tops Q3 Earnings and Revenue Estimates

Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025

NYSE Content Advisory: Pre-Market Update + The AW Playmaker Awards Take the Stage at 11 Wall Street

4 Analysts Assess Nuvation Bio: What You Need To Know

Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer

Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer

Nuvation Bio to Participate in Upcoming Investor Conferences

Nuvation Bio Inc. (NUVB) Just Flashed Golden Cross Signal: Do You Buy?

Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

Acadia Pharmaceuticals (ACAD) Tops Q2 Earnings and Revenue Estimates

Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

JMP Maintains “Market Outperform” on Nuvation (NUVB) for IBTROZI Launch Plans

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers

Are These 2 'Strong Buy' Rated Growth Stocks Buys Right Now?